Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript

OPNET TECHNOLOGIES INC (OPNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/22/2021 GN Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
02/08/2021 GN Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
12/14/2020 GN Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
12/10/2020 GN Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
12/07/2020 GN Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
08/31/2020 GN Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference
08/06/2020 GN Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update
06/05/2020 GN Opiant Pharmaceuticals Statement on U.S. District Court Decision
05/26/2020 GN Opiant Pharmaceuticals to Present at the 2020 Jefferies Virtual Healthcare Conference
05/21/2020 GN Opiant Pharmaceuticals to Hold Virtual 2020 Annual Shareholder Meeting
05/12/2020 GN Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update
04/28/2020 GN Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12
03/04/2020 GN Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
01/02/2020 GN Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose
12/12/2019 GN Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
11/12/2019 GN Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
09/24/2019 GN Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
08/27/2019 GN Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences
04/08/2019 GN Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
04/03/2019 GN Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
04/01/2019 GN Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
03/21/2019 GN Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
12/26/2018 GN Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
12/24/2018 GN Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
11/19/2018 GN New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
11/05/2018 GN Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
10/29/2018 GN Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
09/26/2018 GN Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
09/25/2018 GN Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09/24/2018 GN Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
09/10/2018 GN Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
08/16/2018 GN Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of Influence
08/09/2018 GN Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/25/2018 GN Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy